AM‐Pharma Announces Appointment of Industry Expert Guido Magni as Board Member

March 16 2012 | Category: Appointment

Bunnik, The Netherlands, 16 March 2012. AM‐Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of recombinant human Alkaline Phosphatase (AP) for treatment of Acute Kidney Injury and inflammatory bowel diseases, has appointed Dr Guido Magni as a member of its Supervisory Board.

Dr Magni MD PhD was trained as an MD with a specialization in neuropharmacology. He was previously the global head of the medical science department of Roche Pharmaceuticals, Basel, Switzerland, a post he held for 12 years. During this time he was responsible for the development and the approval of a large number of New Molecular/Biological Entities including Cellcept, Pegasys, Xeloda, Herceptin, Tamiflu, Tarceva and Mabthera. In his position as global head he defined and ensured the implementation of the overall strategies, goals and objectives of the department, with responsibility for drug development from first in human trials right through to registration and post‐marketing approval. Dr Magni also is venture partner of Versant, with oversight of Versant’s European activities. Furthermore, Dr Magni serves as a board member of Biotie and was a board member of Adolor Corporation, recently sold to Cubist, and Anabasis, recently sold to Dompe. Dr Magni is the author of more than 100 papers published in internationally peer reviewed journals.

David Brister, who has been a supervisory board member of AM‐Pharma for 3 years, will step down from the board.

Erik van der Berg, CEO of AM‐Pharma, said: “Guido has a wealth of experience in pharmaceutical drug development combined with a global network in both the research and pharmaceutical community as well as in the venture capital community. We are delighted to have attracted someone with his experience to our board. I also thank David for his valuable contribution over the last 3 years.”

Dr Magni, commenting on his appointment, said: “AM‐Pharma has embarked on a robust development plan for its recombinant human Alkaline Phosphatase for the treatment of Acute Kidney Injury, and has shown very promising data in this large unmet medical need. The board members and management team have an outstanding reputation and I am very pleased to join this excellent team.”

Download this press release (88 kB, pdf)

Latest News

October 24 2018
JAMA publishes Phase II recAP data for sepsis-associated Acute Kidney Injury
Read more.

March 9 2018
AM-Pharma announces Phase II study results of recAP in sepsis-associated Acute Kidney Injury
Read more.

News Categories


Upcoming Events

For a full list of the events we will be attending this year
Click here.